The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin.

Autor:	Yoon HI; University of British Columbia James Hogg Research Center and the Providence Heart and Lung Institute at St. Paul's Hospital, Vancouver, BC, Canada; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea; Department of Medicine, Pulmonary Division, Vancouver, BC, Canada., Li Y; University of British Columbia James Hogg Research Center and the Providence Heart and Lung Institute at St. Paul's Hospital, Vancouver, BC, Canada., Man SFP; University of British Columbia James Hogg Research Center and the Providence Heart and Lung Institute at St. Paul's Hospital, Vancouver, BC, Canada., Tashkin D; University of California at Los Angeles School of Medicine, Los Angeles, CA., Wise RA; Johns Hopkins University School of Medicine, Baltimore, MD., Connett JE; University of Minnesota School of Public Health, Minneapolis, MN., Anthonisen NA; Department of Medicine, University of Manitoba, Winnipeg, MB, Canada., Churg A; Department of Pathology, University of British Columbia, Vancouver, BC, Canada., Wright JL; Department of Pathology, University of British Columbia, Vancouver, BC, Canada., Sin DD; University of British Columbia James Hogg Research Center and the Providence Heart and Lung Institute at St. Paul's Hospital, Vancouver, BC, Canada. Electronic address: don.Sin@hli.ubc.ca.
Jazyk:	angličtina
Zdroj:	Chest [Chest] 2012 Oct; Vol. 142 (4), pp. 893-899.
DOI:	10.1378/chest.11-2173
Abstrakt:	Background: COPD is a chronic inflammatory disorder with high risk of cardiovascular morbidity and mortality. Adiponectin is a hormone that has anti inflammatory, antidiabetic, and anti atherogenic activities. We investigated the relationship of serum adiponectin to health outcomes in COPD. Methods: We measured adiponectin levels in serum samples from participants of the Lung Health Study, who were smokers with mild to moderate airflow limitation. We determined the relationship of serum adiponectin to hospitalization and mortality using a Cox proportional hazards model and to baseline lung function measurements and bronchial reactivity using multiple regression methods. Results: Serum adiponectin concentrations were inversely related to hospitalizations and mortality from coronary heart disease (hazard ratio [HR], 0.73; 95% CI, 0.62-0.86) and to cardiovascular disease (HR, 0.83; 95% CI, 0.73-0.94) and positively related to deaths from respiratory causes (HR, 2.09; 95% CI, 1.41-3.11). However, serum adiponectin concentrations were not significantly related to total mortality (HR, 1.10; 95% CI, 0.93-1.29) or cancer-related mortality(HR, 1.11; 95% CI, 0.92-1.34). Serum adiponectin concentrations were significantly related to increased bronchial reactivity and an accelerated decline in lung function (both P , .0001). Smoking status had no material influence on serum adiponectin concentrations. Conclusions: Adiponectin is a complex serum biomarker in COPD that is associated with decreased risk of cardiovascular events but increased risk of respiratory mortality. Because serum adiponectin is not significantly influenced by smoking status, it is a very promising biomarker of cardiovascular outcomes in COPD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu